# CBD for Individuals at Risk for Alzheimer's Disease

> **NCT05822362** · PHASE2 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 236 (estimated)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** Cannabidiol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05822362
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-19
- **Primary completion:** 2028-04
- **Final completion:** 2029-04
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05822362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05822362, "CBD for Individuals at Risk for Alzheimer's Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05822362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*